Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | -5.78% | 68.46 | 1.0% | $1418.97m | |
| BIIB | Biogen, Inc. | -1.30% | 306.07 | 1.5% | $626.44m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.04% | 431.79 | 2.6% | $525.20m | |
| AMGN | Amgen, Inc. | -2.25% | 198.92 | 1.3% | $514.57m | |
| ILMN | Illumina, Inc. | 0.29% | 260.68 | 3.5% | $396.99m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.23% | 220.56 | 1.9% | $344.15m | |
| MRNA | Moderna, Inc. | -12.54% | 22.88 | 0.0% | $330.57m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.60% | 91.54 | 2.0% | $219.39m | |
| CODX | Co-Diagnostics, Inc. | -17.48% | 13.17 | 0.0% | $204.14m | |
| A | Agilent Technologies, Inc. | -1.80% | 76.04 | 1.6% | $166.72m | |
| EXAS | EXACT Sciences Corp. | 1.69% | 82.19 | 24.0% | $166.39m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.51% | 89.36 | 4.3% | $114.15m | |
| INCY | Incyte Corp. | -2.35% | 74.06 | 2.5% | $107.79m | |
| SGEN | Seattle Genetics, Inc. | 0.69% | 109.06 | 6.1% | $106.63m | |
| NVAX | Novavax, Inc. | 19.83% | 14.14 | 184.0% | $78.77m |
Company Profile
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.